2-{9-(10-Bromoanthracenyl)}-1,3-dihydro-1H-[d]-1,3,2-benzodiazaborole

Round 1

Reviewer 1 Report

According to my opinion, the manuscript entitled "2-{9-(10-Bromoanthracenyl)}-1,3-dihydro-1H-[d]-1,3,2-benzodiazaborole, given by Siphamandla Sithebe does not merit to be published in Molbank. The obtained compound was thoroughly characterized, but I do not understand what for such compounds are obtained. Using such an approach, we can publish almost everything, infinitely. To sum up, without particular application and preapplication tests, e.g. for bioimiging or organic electronics, I do not see any reason for such work. Additionally, such publications negatively influence on Molbank impact factor.

Author Response

the review has pointed out that he/she does not understand what for such compounds are obtained.

My response: The title compound is one of the intermediate novel compounds used as the starting material for the synthesis of a series of 9-aryl-substituded-1,3-dihydro-1H-[d]-1,3,2-benzodiazaborole compounds  which inturn have applications and preapplication tests. One of the reasons why the title compound was not publishable along other analogues is that it did crystalize.

To the best of my knowledge, Molbank caters and publishes short notes of experimental data of novel unpublished single molecule such as the title compound.

Reviewer 2 Report

Siphamandla Sithebe reported synthesis and characterization of 2-{9-(10-Bromoanthracenyl)}-1,3-dihydro-1H-[d]-1,3,2-benzodiazaborole to improve photophysical properties in solid state by possible prevention of π-π stacking between aromatics. Overall, this article is worth to publish in the journal "Molbank". 

Comments:

Line 22: Abbreviation of OLEDs should be Organic Light Emitting Diodes

Line 92, 94, 95: Standard abbreviation for deuterated chloroform used in journals are CDCl₃ instead of DCCl₃. Authors should correct that.

Supporting information: 

It's a general practice to include ¹H NMR spectra from 0-15 ppm (if possible, with clear splitting patterns), ¹³C NMR from 0-200 ppm. Authors should include this in the NMR spectra. In the figure titles, it will be easier to interpret the spectra if we can see the NMR solvent used in the title. Authors should include the deuterated solvent used to take that particular NMR spectra in the figure titles.

Author Response

Line 22: Abbreviation of OLEDs has been changed to  Organic Light Emitting Diodes.

Line 92, 94, 95: Standard abbreviation for deuterated chloroform have been changed from  DCCl₃ to CDCl_3.

_{¹H NMR spectra from 0-15 ppm has been included with splitting patterns.}

_{¹³C NMR from 0-200 ppm has been included with clearly labelled CDCl3 solvent.}

 

 

Round 2

Reviewer 1 Report

Dear Editor, I do not change my former opinion.

 

Author Response

• The formation of the titled compound was changed to the formation of the synthesized compound.
• In the FT-IR of the titled compound was changed to In the FT-IR of the  compound.
• The novel titled compound was changed to The novel compound.
• mass in grams has been included next to a %yield.